Patents by Inventor Stephen P. L. Cary
Stephen P. L. Cary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165197Abstract: Described herein are methods for treating cardiovascular and pulmonary conditions, e.g., those associated with hypoxia, or treating a subject undergoing cardiac or respiratory arrest or cardiopulmonary resuscitation, using an H-NOX protein (or a mixture of H-NOX proteins), or using a combination of an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine). Also described are compositions comprising an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine).Type: ApplicationFiled: September 28, 2023Publication date: May 23, 2024Inventors: Stephen P.L. Cary, Natacha Le Moan, Ana Krtolica, Jonathan A. Winger
-
Patent number: 11987614Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: GrantFiled: August 9, 2021Date of Patent: May 21, 2024Assignee: OMNIOX, INC.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Publication number: 20240026399Abstract: The invention provides H-NOX proteins for the delivery of oxygen to hypoxic tissue following stroke. H-NOX proteins extravasate into hypoxic penumbra associated with stroke and preferentially accumulate for sustained delivery of oxygen to the hypoxic tissue to ameliorate adverse affects of stroke related hypoxia. In some embodiments, the H-NOX comprises PEGylated H-NOX and non-PEGylated H-NOX.Type: ApplicationFiled: April 27, 2023Publication date: January 25, 2024Inventors: Natacha LE MOAN, Ana KRTOLICA, Philberta LEUNG, Stephen P.L. CARY
-
Publication number: 20220160823Abstract: The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1?) pathways and non-HIF-1? pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.Type: ApplicationFiled: December 10, 2021Publication date: May 26, 2022Inventors: Stephen P. L. CARY, Ana KRTOLICA, Natacha LE MOAN, Jonathan A. WINGER, Kevin G. LEONG
-
Publication number: 20220048977Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: ApplicationFiled: August 9, 2021Publication date: February 17, 2022Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Patent number: 11117952Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: GrantFiled: July 17, 2020Date of Patent: September 14, 2021Assignee: OMNIOX, INC.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Publication number: 20210260155Abstract: Described herein are methods for treating cardiovascular and pulmonary conditions, e.g., those associated with hypoxia, or treating a subject undergoing cardiac or respiratory arrest or cardiopulmonary resuscitation, using an H-NOX protein (or a mixture of H-NOX proteins), or using a combination of an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine). Also described are compositions comprising an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine).Type: ApplicationFiled: February 12, 2021Publication date: August 26, 2021Inventors: Stephen P.L. Cary, Natacha Le Moan, Ana Krtolica, Jonathan A. Winger
-
Publication number: 20210121521Abstract: The invention provides H-NOX proteins for the delivery of oxygen to hypoxic tissue following stroke. H-NOX proteins extravasate into hypoxic penumbra associated with stroke and preferentially accumulate for sustained delivery of oxygen to the hypoxic tissue to ameliorate adverse affects of stroke related hypoxia. In some embodiments, the H-NOX comprises PEGylated H-NOX and non-PEGylated H-NOX.Type: ApplicationFiled: December 23, 2020Publication date: April 29, 2021Applicant: Omniox, Inc.Inventors: Natacha Le Moan, Ana Krtolica, Philberta Leung, Stephen P. L. Cary
-
Publication number: 20210002351Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: ApplicationFiled: July 17, 2020Publication date: January 7, 2021Applicant: Omniox, Inc.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Patent number: 10766947Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: GrantFiled: June 24, 2019Date of Patent: September 8, 2020Assignee: Omniox, Inc.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Publication number: 20200276265Abstract: The invention provides H—NOX proteins for the delivery of oxygen to hypoxic tissue following stroke. H—NOX proteins extravasate into hypoxic penumbra associated with stroke and preferentially accumulate for sustained delivery of oxygen to the hypoxic tissue to ameliorate adverse affects of stroke related hypoxia. In some embodiments, the H—NOX comprises PEGylated H—NOX and non-PEGylated H—NOX.Type: ApplicationFiled: February 16, 2017Publication date: September 3, 2020Applicant: Omniox, Inc.Inventors: Natacha Le Moan, Ana Krtolica, Philberta Leung, Stephen P.L. Cary
-
Publication number: 20200017574Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: ApplicationFiled: June 24, 2019Publication date: January 16, 2020Applicant: Omniox, Inc.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Patent number: 10385116Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: GrantFiled: January 7, 2013Date of Patent: August 20, 2019Assignee: Omniox, Inc.Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
-
Patent number: 10202428Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: October 12, 2016Date of Patent: February 12, 2019Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20180243364Abstract: The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1?) pathways and non-HIF-1? pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.Type: ApplicationFiled: March 17, 2016Publication date: August 30, 2018Inventors: Stephen P. L. CARY, Ana KRTOLICA, Natacha LE MOAN, Jonathan A. WINGER, Kevin G. LEONG
-
Publication number: 20170267732Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: October 12, 2016Publication date: September 21, 2017Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA
-
Patent number: 9493526Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: September 17, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Patent number: 9493527Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: GrantFiled: September 18, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20160185839Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.Type: ApplicationFiled: January 7, 2013Publication date: June 30, 2016Applicant: Omniox, Inc.Inventors: Gregory KAPP, Laura SERWER, Natacha LE MOAN, Stephen P.L. CARY
-
Publication number: 20150376250Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: September 17, 2014Publication date: December 31, 2015Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA